@article{46da353804294978a0f6fa14028016ba,
title = "The Challenge of Blau Syndrome",
author = "Holland, {Gary N.} and Rosenbaum, {James T.}",
note = "Funding Information: Funding/Support: Supported by the Skirball Foundation, New York, New York (G.N.H.) and Research to Prevent Blindness, Inc., New York, New York (G.N.H., J.T.R.). J.T.R. also received support from the William and Mary Bauman Foundation (Wilsonville, Oregon) and the Stan and Madelle Rosenfeld Family Trust (Portland, Oregon). Funding entities had no role in the preparation of this Editorial. Financial Disclosures: James T. Rosenbaum has received financial support for research and consultation activities from AbbVie, Inc (North Chicago, Illinois); Gilead Sciences, Inc (Foster City, California); Regeneron Pharmaceuticals, Inc (Tarrytown, New York); UCB Biosciences, Inc (Raleigh, North Carolina); Eyevensys (Paris, France); TopiVert Pharma Limited (London, UK); and Cavtherx, Inc (San Francisco, California); has received royalties from UpToDate, Inc (Waltham, Massachusetts); and is on the Speakers Bureau for Mallincrokdt Pharmaceuticals (St. Louis, Missouri).The following author has no financial disclosures: Gary N. Holland. The authors attest that they meet the current ICMJE criteria for authorship.",
year = "2018",
month = mar,
doi = "10.1016/j.ajo.2017.12.006",
language = "English (US)",
volume = "187",
pages = "xviii--xix",
journal = "American journal of ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
}